allogeneic crispr-cas9 engineered anti-cd19 car t-cells ctx112 vs obexelimab
| allogeneic crispr-cas9 engineered anti-cd19 car t-cells ctx112 | obexelimab | |
|---|---|---|
| Developers | 0 | 1 |
| Clinical trials | 0 | 1 |
| FDA decisions | 0 | 0 |
| Generic name | Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T-cells CTX112 | — |